inactivated influenza vaccine

Vaccineapproved

Approved

Nov 3, 1998

Influenza vaccines, colloquially known as flu shots or the flu jab, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza. Vaccination against influenza began in the 1930s, with large-scale availability in the United States beginning in 1945. — Wikipedia

Clinical trial activity

1,118 trials · 505 clinical orgs · 4 marketing orgs

Phase 1
236
Phase 2
564
Phase 3
270
Phase 4
273

Earliest trial started Oct 1, 1998 (NCT00138294)

Timeline

1940s

  1. Jul 1, 1945

    Evidence of US Marketing

1990s

  1. Nov 3, 1998

    Earliest FDA Approval

  2. Nov 3, 1998

    CSL Behring — NDA Secondary Org

  3. Dec 9, 1999

    Sanofi-Aventis — NDA Secondary Org

2000s

  1. Jan 1, 2002

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Dec 14, 2012

    GlaxoSmithKline — First NDA Organization

  2. Dec 14, 2012

    GlaxoSmithKline — NDA Organization

  3. Jan 16, 2013

    Protein Sciences Corp — NDA Secondary Org

Indications

Studied for

Mechanism of action

  • Influenza A virus other

  • Influenza virusImmunity, active

    Influenza virus immunity, active

  • Influenza A virusImmunity, active

    Influenza A virus immunity, active

  • Unspecified targetUnclear

    unclear

  • Unspecified targetOTHER

    Biological vaccine - induces immune response

Approval history

  • approvedNov 3, 1998
  • approvedJul 1, 1945

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • a/17/ca/2009/38 (h1n1)
  • adimflu-s
  • adimflu-v
  • adimflu-w (h5n1)
  • adjuvanted h1n1 influenza vaccine
  • adjuvanted h1n1 influenza virus vaccine
  • adjuvanted h5n1 influenza virus vaccine
  • adjuvanted h5n1 pandemic influenza vaccine
  • adjuvanted inactivated novel swine origin a/h1n1 monovalent subunit influenza virus vaccine
  • adjuvanted inactivated whole virion h5n1 vaccine
  • adjuvanted seasonal trivalent inactivated influenza vaccine
  • adjuvanted trivalent subunit influenza vaccine
  • afluria
  • a/h1n1 influenza vaccine
  • a(h1n1) influenza vaccine
  • a/h1n1 influenza vlp vaccine
  • a/h1n1 pandemic influenza vaccine
  • a/h1n1 vaccine
  • a/h5n1 inactivated, split-virion influenza vaccine
  • a/h5n1 vaccine
  • a/indonesia/05/2005 (h5n1) like strain used (pr8-ibcdc-rg2)
  • anti-influenza vaccine
  • asp7374
  • a/turkey h5n1 influenza vaccine
  • a/turkey h5n1 vaccine
  • begrivac
  • butantan fragmented inactivated trivalent influenza vaccine
  • cell-derived a/h1n1 influenza ha vaccine
  • egg-derived h5n1 influenza vaccine
  • egg-derived trivalent inactivated subunit influenza vaccine
  • eh1n1
  • eh1n1_f
  • eh5n1
  • enzira
  • etiv-h5n1
  • fcc h5n1
  • fluad
  • fluad
  • fluad h5n1
  • flucelvax
  • flucelvax
  • fluenz
  • fluenz tetra
  • fluenz tretra
  • fluogen
  • flushield
  • flushield
  • fluviral
  • fluvirin
  • fluzone
  • fluzone
  • fluzone
  • fluzone quadrivalent
  • foceteria
  • focetria
  • gc3102c
  • gc3110
  • gcflu
  • gc flu
  • gsk1557482a
  • gsk1557484a
  • gsk1557484a
  • gsk 1557484a
  • gsk-1557484a
  • gsk2282512a
  • gsk2340273a
  • gsk2340274a
  • gsk576389a
  • h1n1 influenza vaccine
  • h1n1 influenza virus vaccine
  • h1n1 pandemic influenza vaccine
  • h1n1 vaccine
  • h3n2 m2sr monovalent influenza vaccine
  • h3n2v inactivated subvirion influenza vaccine
  • h5n1 (6-2) aa ca recombinant
  • h5n1 influenza vaccine
  • h5n1 vaccine
  • h7n9 a/anhui/13 ca influenza virus vaccine
  • h7n9 influenza vaccine
  • h7n9 live influenza vaccine
  • h9n2 (6-2) aa ca reassortant
  • h9n2 influenza vaccine
  • h9n2 virosomal vaccine
  • hai-05 influenza vaccine
  • inactivated adjuvanted influenza vaccine
  • inactivated h1n1 vaccine
  • inactivated influenza a/h5n1 vaccine
  • inactivated influenza h1n1 vaccine
  • inactivated influenza h5n1 vaccine
  • inactivated influenza split vaccine
  • inactivated influenza vaccine
  • inactivated influenza vaccine trivalent types a and b
  • inactivated quadrivalent influenza vaccine
  • inactivated seasonal flu vaccine
  • inactivated seasonal influenza vaccine
  • inactivated split influenza vaccine
  • inactivated, split-virion influenza vaccine
  • inactivated split virus seasonal influenza vaccine
  • inactivated subvirion h7n9 influenza vaccine
  • inactivated trivalent influenza vaccine
  • inactivated vero cell based whole virus influenza a/h5n1
  • inactived influenza vaccine
  • influenza a/california/04/2009
  • influenza a/h1n1 2009
  • influenza a h1n1 split virion vaccine
  • influenza a h1n1 whole virus vaccine
  • influenza a h7n7 vaccine
  • influenza a/vietnam/1203/2004
  • influenza h1n1 monovalent vaccine
  • influenza h3n2 monocalen vaccine
  • influenza h5n1 virus monovalent vaccine
  • influenza h9n2 vaccine
  • influenza, live attenuated
  • influenza split vaccine
  • influenza vaccine
  • influenza vaccine, adjuvanted
  • influenza vaccine, adjuvanted
  • influenza vaccines
  • influenza vaccine, split inactivated
  • influenza vaccine surface antigen
  • influenza vaccine trivalent inactivated
  • influenza vaccine, trivalent (tiv)
  • influenza vaccine (whole virion, inactivated) containing antigen of: a/vietnam/1203/2004 (h5n1)
  • influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type)
  • influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain(a/brisbane/10/2010, wild type)a/switzerland/9715293/2013 (h3n2) - like strain(a/south australia/55/2014, wild type)b/phuket/3073/2013like strain(b/utah/9/2014, wild type)
  • influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 7.5 microgragms per 0.5 ml dose
  • influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23)
  • influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1)
  • influenza virus surface antigens, inactivated: a/viet nam/1194/2004 (h5n1)
  • influenza virus vaccine
  • influenza virus vaccine
  • influenza virus vaccine
  • influenza virus vaccine, h5n1
  • influenza virus vaccine, monovalent a/h1n1 a/california/7/2009 nymc x-179a
  • influenza virus vaccine, monovalent a/h5n1 a/indonesia/05/2005
  • influenza virus vaccine, monovalent a/h7n9 a/shanghai/2/2013
  • influenza virus vaccine, reassorted
  • influenza virus (whole virion, inactivated), containing antigen of: a/vietnam/1203/2004 (h5n1)
  • influvac
  • ivacflu
  • laiv h2n2
  • laiv h5n2
  • live attenuated h7n9 a/anhui/13 ca influenza virus vaccine
  • mas-1
  • mg1109
  • monovalen inactivated h1n1 virus vaccine
  • monovalent h5n1 influenza vaccine
  • monovalent influenza a/h5n8 vaccine
  • monovalent influenza a/h7n9 virus vaccine
  • monovalent influenza subunit virion (h5n1) vaccine, a/indonesia/05/2005
  • monovalent influenza subunit virion (inactive h5n1) vaccine
  • monovalent influenza subvirion vaccine, h7n7
  • monovalent influenza vaccine
  • monovalent live attenuated pandemic influenza vaccine
  • monovalent subvirion a/h1n1 influenza vaccine
  • nactived influenza vaccine
  • nasovac-s
  • nbp607
  • pandemic influenza a (h1n1) vaccine
  • pandemic influenza a/h1n1 vaccine
  • pandemic influenza a/h5n1 vaccine
  • pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted)
  • pandemic influenza vaccine (h5n1 strain nibrg-14)
  • pandemrix
  • pandemrix
  • qiv
  • qiv
  • quadrivalent cell-culture based influenza vaccine
  • quadrivalent cell-culture influenza vaccine
  • quadrivalent inactivated influenza vaccine
  • quadrivalent inactivated influenza virus vaccine
  • quadrivalent influenza vaccine
  • quadrivalent influenza virus vaccine
  • quadrivalent subunit influenza virus vaccine
  • quadrivalent virosomal influenza vaccine
  • reassortant influenza virus (live attenuated) of the following four strains:a/california/7/2009 (h1n1)pdm09 - like strain(a/bolivia/559/2013, medi 255962)a/hong kong/4801/2014 (h3n2) - like strain(a/new caledonia/71/2014, medi 263122)b/brisbane/60/2008 - like strain(b/brisbane/60/2008, medi 228030)b/phuket/3073/2013 - like strain(b/phuket/3073/2013, medi 254977)
  • reassortant influenza virus (live attenuated) of the following strain: a/vietnam/1203/2004 (h5n1) strain
  • reassortant influenza virus (live attenuated) of the following strains: a/california/7/2009 (h1n1)pdm09 like strain, a/victoria/361/2011 (h3n2) like strain, b/massachusetts/2/2012 like strain
  • reassortant vaccine virus nymc x-179a
  • recombinant influenza ha vaccine (h5n1)
  • recombinant live-attenuated influenza h2n2 virus vaccine
  • reverse genetic reassortant a/h9n2 influenza vaccine
  • rhao trivalent influenza vaccine
  • sanofi a(h1n1) vaccine
  • seasonal inactivated influenza vaccine
  • seasonal split influenza vaccine
  • seasonal trivalent inactivated influenza vaccine
  • s-oiv h1n1 vaccine
  • split inactivated a/california/7/2009 (h1n1) vaccine
  • split, inactivated, trivalent influenza vaccine
  • split influenza virus, inactivated, containing antigen* : a/california/7/2009 (h1n1)v like strain (x-179a) * produced in eggs
  • split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a) *propagated in eggs.
  • split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14)
  • split influenza virus inactivated, containing antigen equivalent to a/california/07/2009 (h1n1)-derived strain used nymc x-179a
  • split influenza virus vaccine
  • split-virion, adjuvanted h1n1 vaccine
  • split-virion, adjuvanted h5n1 vaccine
  • split-virion, h1n1 vaccine
  • split virion, inactivated influenza vaccine
  • split-virion, non-adjuvanted h1n1 vaccine
  • subvirion a/h1n1 influenza vaccine
  • subvirion a/h5n1 influenza vaccine
  • subvirion inactivated influenza a/h9n2
  • surface antigen, inactivated, adjuvanted influenza vaccine
  • swine a/h1n1 influenza vaccine
  • trivalent baculovirus-expressed influenza ha vaccine
  • trivalent cell-culture based influenza vaccine
  • trivalent inactivated flu vaccine
  • trivalent inactivated influenza vaccine
  • trivalent inactivated influenza virus vaccine
  • trivalent influenza split vaccine
  • trivalent influenza vaccine
  • trivalent influenza virus vaccine
  • trivalent seasonal influenza vaccine
  • trivalent split influenza vaccine
  • trivalent split influenza virus
  • trivalent subunit inactivated influenza vaccine
  • un-adjuvanted influenza a(h1n1) vaccine
  • vaccine h1n1
  • vaxigrip
  • vero cell-derived influenza vaccine
  • whole-virion, adjuvanted h1n1 vaccine
  • whole-virion, adjuvanted h5n1 vaccine
  • whole virion, inactivated containing antigen: a/california/07/2009 (h1n1)v
  • whole virion, inactivated, containing antigen*: a/vietnam/1194/2004 (h5n1) * produced in eggs

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07215858Phase 2Mar 2, 2026National Institute of Allergy and Infectious Diseases (NIAID)
NCT07291635Phase 1/Phase 2 (Phase 2)Feb 28, 2026Aramis Biotechnologies Inc., McGill University
NCT07305207Phase 1Feb 1, 2026Canadian Center for Vaccinology, Dalhousie University, McGill University
NCT07259252N/ADec 1, 2025Huazhong University of Science and Technology
NCT07211152Phase 3Nov 30, 2025Sinovac Biotech Co., Ltd
NCT07300085Phase 1Nov 8, 2025Cidara Therapeutics
NCT06824779Phase 4Oct 31, 2025Sanofi-Aventis, University of Lyon
NCT07192458Phase 2Sep 17, 2025Vanderbilt University
NCT07177417Phase 4Sep 9, 2025AstraZeneca, Washington University in St. Louis
NCT06842173Phase 1/Phase 2 (Phase 2)Sep 1, 2025Butantan Foundation, Butantan Institute, Fundação Butantan
NCT06991257Phase 2Jun 19, 2025Pfizer
NCT07019883Phase 1Jun 12, 2025National Institute of Allergy and Infectious Diseases (NIAID)
NCT07063849Phase 1May 20, 2025St. Louis University
NCT06850051Phase 1Mar 19, 2025Sanofi
NCT06864143Phase 2Mar 7, 2025Moderna Therapeutics
NCT06827873N/AFeb 28, 2025Tsinghua University
NCT06821061Phase 1/Phase 2 (Phase 2)Feb 10, 2025Biontech, Pfizer
NCT06800950Phase 3Feb 8, 2025Chinese Academy of Medical Sciences, Government of China
NCT06744205Phase 1/Phase 2 (Phase 2)Jan 7, 2025Sanofi, Sanofi-Aventis
NCT06620185N/AJan 6, 2025Imperial College London, University of London
Showing 20 of 1,118 trials
Page 1 / 56

Organizations

Research & Development (505)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Allergy and Infectious Diseases (NIAID)Government14511351998
NovartisFor profit978651998
SanofiFor profit938042003
GlaxoSmithKlineFor profit928542002
Sanofi-AventisFor profit633341998
Government of ChinaGovernment441352005
CSL BehringFor profit383642005
Centers for Disease Control and Prevention (CDC)Government36852004
Stanford UniversityAcademic/Hospital252142007
Korea UniversityAcademic/Hospital24542009
Sinovac Biotech Co., LtdFor profit242342005
Ology BioservicesFor profit222232003
BaxaltaFor profit20332006
PfizerFor profit201342011
Department of Health and Human ServicesGovernment19232007
National Institutes of Health (NIH)Government19042004
Emory UniversityAcademic/Hospital181252010
Green Cross CorporationFor profit171552009
University of RochesterAcademic/Hospital17752002
Johns Hopkins UniversityAcademic/Hospital16452005
505 organizations
Page 1 / 26

Marketing (4)

OrganizationOrg typeRelationshipDate
CSL BehringFor profitNDA2Nov 3, 1998
GlaxoSmithKlineFor profitNDADec 14, 2012
Protein Sciences CorpFor profitNDA2Jan 16, 2013
Sanofi-AventisFor profitNDA2Dec 9, 1999